The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
PURPOSE: We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity. PATIENTS AND METHODS: Fifty-two patients treated with a bimonthly oxaliplatin-based regimen were randomized to receive GSH (1,500 mg/m 2 over a 15-minute infusion period before oxaliplatin) or normal saline solution. Clinical neurologic evaluation and electrophysiologic investigations were performed at baseline and after four (oxaliplatin dose, 400 mg/m 2), eight (oxaliplatin dose, 800 mg/m 2), and 12 (oxaliplatin dose, 1,200 mg/m 2) cycles of treatment. RESULTS: At the fourth cycle, seven patients showed clinically evident neuropathy in the GSH arm, whereas 11 patients in the placebo arm did. After the eighth cycle, nine of 21 assessable patients in the GSH arm suffered from neurotoxicity compared with 15 of 19 in the placebo arm. With regard to grade 2 to 4 National Cancer Institute common toxicity criteria, 11 patients experienced neuropathy in the placebo arm compared with only two patients in the GSH arm (P = .003). After 12 cycles, grade 2 to 4 neurotoxicity was observed in three patients in the GSH arm and in eight patients in the placebo arm (P = .004). The neurophysiologic investigations (sural sensory nerve conduction) showed a statistically significant reduction of the values in the placebo arm but not in the GSH arm. The response rate was 26.9% in the GSH arm and 23.1% in the placebo arm, showing no reduction in activity of oxaliplatin. CONCLUSION: This study provides evidence that GSH is a promising drug for the prevention of oxaliplatin-induced neuropathy, and that it does not reduce the clinical activity of oxaliplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Glantz, S. A. (1981) · Cited by 2,636
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008347829017 · Cited by 606
Charles F. Kettring prize. Fundamental studies with cisplatin
Rosenberg, B. (1985) · Cancer · doi:10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l · Cited by 517
Regulation of fast inactivation of cloned mammalian IK(A) channels by cysteine oxidation
Ruppersberg, J. P., Stacker, M., Pongs, O., Heinemann, S. H., Frank, R., & Koenen, M. (1991) · Nature · doi:10.1038/352711a0 · Cited by 447
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
Culy, C. R., Clemett, D., & Wiseman, L. R. (2000) · Drugs · doi:10.2165/00003495-200060040-00005 · Cited by 217
Oxaliplatin clinical activity: a review
Misset, J. L., Bleiberg, H., Sutherland, W., Bekradda, M., & Cvitkovic, E. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00070-6 · Cited by 180
Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., & Tedeschi, M. (1997) · Annals of Oncology · doi:10.1023/a:1008211226339 · Cited by 178
Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164
Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1193 · Cited by 159
Cascinu, S., Cordella, L., Ferro, E. D., Fronzoni, M., & Catalano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.26 · Cited by 158
Self-citationZunino, F., Pratesi, G., Micheloni, A., Cavalletti, E., Sala, F., & Tofanetti, O. (1989) · Chemico-Biological Interactions · doi:10.1016/0009-2797(89)90065-3 · Cited by 156
Cavaletti, G., Marzorati, L., Bogliun, G., Colombo, N., Marzola, M. M., Pittelli, M., & Tredici, G. (1992) · Cancer · Cited by 116
Maindrault‐Gœbel, F., de Gramont, A., Louvet, C., André, T., Carola, É., Gilles-Amar, V., Lotz, J., Tournigand, C., Mabro, M., Molitor, J., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026520812351 · Cited by 116
Park, S. A., Choi, K. S., Bang, J. H., Huh, K., & Kim, S. U. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750946.x · Cited by 90
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Dr, G., Perez, E. A., Weibe, et al. (1991) · PubMed · Cited by 75
Cited by
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A. D., Brezault, C., Le Charpentier, M., Dousset, B., Morel, P., Soubrane, O., Chaussade, S., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh095 · Cited by 1,038
Reactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 893
Metadata
- Authors
- Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-15
- Volume
- 20
- Issue
- 16
- Pages
- 3478-3483
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2006613730
- Cited by
- 421
- References
- 22
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.